assembl
cohort
consist
hospit
inform
patient
characterist
antivir
medic
use
hospit
stay
collect
studi
object
evalu
treatment
efficaci
select
antivir
medic
mortal
lesion
absorpt
base
chest
ct
scan
overal
mortal
rate
cohort
older
age
lower
level
bigger
lesion
earli
admiss
data
presenc
preexist
condit
associ
higher
mortal
adjust
sex
preexist
condit
age
lesion
size
admiss
data
hospit
antivir
medic
use
arbidol
oseltamivir
use
associ
reduct
mortal
ci
p
arbidol
ci
oseltamivir
compar
patient
take
neither
arbidol
oseltamivir
ci
patient
take
oseltamivir
ci
p
patient
take
arbidol
ci
patient
take
adjust
patient
characterist
lopinavirritonavir
use
similarli
arbidol
also
associ
faster
lesion
absorpt
adjust
patient
characterist
well
oseltamivir
lopinavirritonavir
use
worldwid
pandem
develop
rapidli
press
need
find
effect
therapi
assembl
cohort
consist
hospit
inform
patient
characterist
antivir
medic
use
hospit
stay
collect
studi
object
evalu
treatment
efficaci
select
antivir
medic
mortal
lesion
absorpt
base
chest
ct
scan
overal
mortal
rate
cohort
older
age
lower
level
bigger
lesion
earli
admiss
data
presenc
preexist
condit
associ
higher
mortal
adjust
sex
preexist
condit
age
lesion
size
admiss
data
hospit
antivir
medic
use
arbidol
oseltamivir
use
associ
reduct
mortal
ci
p
arbidol
ci
oseltamivir
compar
patient
take
neither
arbidol
oseltamivir
ci
patient
take
oseltamivir
ci
p
patient
take
arbidol
ci
patient
take
adjust
patient
characterist
lopinavirritonavir
use
similarli
arbidol
also
associ
faster
lesion
absorpt
adjust
patient
characterist
well
oseltamivir
lopinavirritonavir
use
arbidol
abl
substanti
associ
reduct
mortal
among
hospit
patient
combin
arbidol
oselmativir
may
associ
reduct
mortal
proven
treatment
benefit
lopinavirritonavir
sinc
decemb
first
case
discov
wuhan
china
infect
death
report
sinc
outbreak
research
around
world
activ
search
effect
therapi
urgent
need
control
pandem
associ
reduct
mortal
among
infect
sever
case
report
recoveri
patient
receiv
certain
treatment
howev
lack
data
remain
obstacl
reliabl
evalu
treatment
effect
therapi
attempt
sever
ongo
clinic
trial
whose
complet
howev
requir
time
resourc
uncertain
result
march
chines
nation
health
commiss
issu
new
coronari
viru
pneumonia
diagnosi
treatment
program
version
medic
mention
antivir
treatment
program
includ
lopinavirritonavir
ribavirin
chloroquin
phosphat
arbidol
addit
antivir
drug
includ
oseltamivir
ganciclovir
favipiravir
remdesivir
also
use
clinic
practic
lopinavirritonavir
commonli
use
combin
antiretrovir
drug
treat
hiv
infect
ribavirin
antivir
drug
mainli
use
viral
pneumonia
bronchiti
caus
respiratori
syncyti
viru
chloroquin
phosphat
origin
use
treat
chloroquinesensit
falciparum
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
vivax
malaria
arbidol
mainli
use
treat
upper
respiratori
tract
infect
caus
influenza
viru
oseltamivir
favipiravir
also
primarili
use
treat
influenza
ganciclovir
use
treat
infect
induc
cytomegaloviru
herp
simplex
viru
epsteinbarr
viru
remdesivir
new
drug
whose
antivir
effect
unclear
relev
clinic
trial
still
ongo
pandem
start
wuhan
pulmonari
hospit
wph
becam
one
first
design
hospit
receiv
patient
march
wuhan
tongji
hospit
wuhan
union
hospit
also
design
hospit
treat
larg
number
patient
clinic
experi
battl
three
hospit
may
guid
discoveri
effect
therapi
diseas
studi
object
evalu
treatment
effect
select
antivir
medic
use
real
word
data
collect
hospit
studi
protocol
review
approv
ethic
committe
wph
wpe
patient
record
inform
deidentifi
prior
analysi
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
figur
demonstr
step
construct
cohort
treatment
protocol
three
hospit
includ
lopinavirritonavir
arbidol
earli
protocol
recommend
oseltamivir
develop
epidem
chloroquin
phosphat
favipiravir
also
use
select
patient
prescript
antivir
medic
administr
time
patient
extract
electron
medic
record
studi
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
specif
focu
three
prescrib
medic
arbidol
oselmativir
lopinavirritonavir
collect
data
patient
characterist
known
associ
patient
outcom
includ
age
sex
preexist
condit
etabl
level
hospit
admiss
use
oxygen
ventil
hospit
stay
patient
first
last
avail
ct
scan
imag
primari
endpoint
inhospit
death
whose
time
extract
medic
record
secondari
endpoint
chang
lesion
size
measur
ct
scan
measur
lesion
size
base
first
ct
imag
patient
admiss
initi
regular
fullcours
antivir
treatment
also
measur
lesion
size
base
last
ct
scan
taken
patient
death
discharg
normal
complet
antivir
therapi
cycl
ensur
compar
two
ct
imag
select
plane
largest
lesion
first
ct
scan
took
plane
second
lesion
select
plane
circl
quantifi
efigur
imagej
nih
patient
characterist
baselin
summar
accord
treatment
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
hospit
continu
dichotom
variabl
summar
mean
standard
deviat
sd
count
proport
respect
compar
mortal
rate
patient
receiv
select
medic
use
fisher
exact
test
employ
logist
regress
estim
odd
ratio
associ
medic
adjust
sex
preexist
condit
medic
use
hospit
logtransform
age
level
admiss
data
well
lesion
size
initi
ct
scan
miss
covari
imput
median
observ
valu
also
perform
sensit
analysi
evalu
causal
effect
treatment
use
doubli
robust
method
analysi
restrict
patient
whose
estim
propens
score
also
repeat
logist
regress
patient
wph
potenti
sampl
bia
lowest
check
good
fit
logist
regress
hosmerlemeshow
test
addit
perform
cox
regress
analys
time
depend
covari
set
valu
medic
prescript
respect
account
time
medic
use
also
conduct
linear
regress
analys
logtransform
ratio
lesion
area
second
ct
scan
first
outcom
studi
effect
antivir
medic
lesion
absorpt
among
surviv
patient
small
valu
one
ad
lesion
size
avoid
logtransform
zero
twosid
statist
signific
level
set
statist
analys
conduct
use
r
r
foundat
statist
comput
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
cohort
consist
patient
confirm
infect
three
hospit
patient
wph
patient
tongji
hospit
patient
union
hospit
tabl
femal
preexist
condit
averag
age
cohort
sd
year
old
averag
level
admiss
patient
admit
hospit
earli
like
receiv
oseltamivir
lopinavirritonavir
overal
mortal
rate
mortal
among
femal
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
figur
summar
analysi
result
three
medic
efigur
show
distribut
lesion
absorpt
rate
medic
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
patient
wph
patient
took
neither
arbidol
oseltamivir
patient
took
arbidol
order
studi
causal
effect
arbidol
compar
mortal
two
group
exclud
patient
estim
propens
score
base
sex
preexist
condit
log
age
log
log
baselin
lesion
size
log
admiss
data
lopinavirritonavir
use
greater
less
doubli
adjust
mortal
estim
ci
patient
take
neither
ci
patient
take
arbidol
compar
patient
take
neither
ci
p
favor
arbidol
etabl
summar
patient
characterist
treatment
propens
score
reweight
patient
wph
mortal
among
patient
take
arbidol
vs
among
ci
p
adjust
sex
preexist
condit
log
age
log
log
lesion
area
log
admiss
data
antivir
medic
use
arbidol
significantli
associ
reduct
mortal
ci
analys
treatment
effect
arbidol
reduc
mortal
among
hospit
patient
strong
robust
combin
use
arbidol
oseltamivir
appear
abl
associ
reduct
mortal
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
addit
patient
take
arbidol
show
faster
lesion
absorpt
consist
effect
mortal
hand
benefit
lopinavirritonavir
inconclus
consist
find
cao
et
al
lopinavirritonavir
associ
reduct
mortal
random
clinic
trial
fail
reach
statist
signific
threshold
recent
xu
et
al
report
virolog
convers
rate
patient
take
arbidol
significantli
higher
patient
receiv
standard
care
vs
studi
patient
take
arbidol
also
higher
chanc
achiev
lesion
area
absorpt
ct
imag
vs
despit
limit
sampl
size
result
corrobor
find
arbidol
duo
role
inhibit
fusion
viral
envelop
target
host
cell
membran
antiinflamm
may
respons
efficaci
oseltamivir
normal
prescrib
treat
influenza
known
effect
patient
howev
influenza
clinic
similar
patient
infect
common
influenza
may
exacerb
clinic
condit
possibl
combo
therapi
includ
oseltamivir
help
subgroup
patient
due
effect
oseltamivir
treat
sever
ill
caus
influenza
sever
import
limit
current
studi
studi
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
random
clinic
trial
therefor
estim
treatment
benefit
arbidol
oseltamivir
may
due
confound
effect
collect
inform
known
confound
includ
age
comorbid
admiss
data
diseas
sever
measur
ct
scan
howev
alway
risk
unmeasur
confound
explain
observ
treatment
effect
hand
given
size
observ
benefit
unmeasur
confound
effect
need
strong
complet
account
estim
benefit
secondli
nt
account
effect
import
support
treatment
oxygen
ventil
use
avail
deploy
may
affect
estim
treatment
effect
thirdli
although
cohort
size
small
patient
tongji
union
hospit
necessarili
repres
sampl
patient
admit
hospit
exampl
icu
patient
two
hospit
includ
also
exclud
surviv
patient
discharg
wph
consequ
observ
mortal
rate
among
patient
wph
cohort
substanti
higher
among
patient
admit
wph
sampl
bias
may
affect
generaliz
find
furthermor
patient
take
arbidol
oseltamivir
entir
cohort
limit
reliabl
estim
treatment
benefit
associ
combin
therapi
hand
despit
limit
sampl
size
select
sampl
identifi
risk
factor
current
studi
consist
literatur
indirectli
support
valid
find
treatment
efficaci
associ
admiss
data
mortal
also
explain
increas
medic
resourc
lastli
regard
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
advers
event
case
nausea
observ
patient
receiv
arbidol
loss
appetit
observ
among
patient
receiv
oseltamivir
diarrhea
nausea
vomit
loss
appetit
worsen
sleep
qualiti
observ
patient
receiv
lopinavirritonavir
howev
sinc
larg
proport
patient
receiv
multipl
medic
due
complex
natur
advers
event
studi
team
summar
data
report
hand
arbidiol
oseltamivir
use
treat
influenza
patient
mani
year
sever
advers
event
associ
medicin
rare
conclus
cohort
patient
three
hospit
arbidol
alon
combin
oseltamivir
associ
drastic
associ
reduct
mortal
account
observ
confound
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
adjust
sex
preexist
condit
log
age
log
hospit
log
lesion
size
log
admiss
data
model
adjust
confound
model
medic
use
arbidol
oseltamivir
lopinavirritonavir
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
comparison
good
fit
test
logist
regress
model
statist
medicin
xu
r
luo
chamber
c
assess
effect
vaccin
spontan
abort
use
time
depend
covari
cox
model
pharmacoepidemiolog
drug
safeti
ccbynd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
